Whole-process 3D ECM-encapsulated organoid-based automated high-throughput screening platform accelerates drug discovery for rare diseases
Life Medicine · 08.10.2025 · 4 (5)
DOI: 10.1093/lifemedi/lnaf021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life Medicine, online erschienen am 14.06.2025. Verfasst von Zhaoting Xu und 4 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai 200438, China. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Organoid-based high-throughput screening (HTS) is revolutionizing pharmaceutical development. However, the complexity of handling extracellular matrix (ECM) components with traditional HTS devices leads to the use of suspension cultures for organoids during HTS, which alters their transcriptomic landscape and drug responses. Although automated generation techniques for 3D ECM-encapsulated organoids have been established, limitations in operational simplicity and time efficiency remain barriers to achieving high throughput. Here, we develop a whole-process 3D ECM-encapsulated organoid-based automated HTS (wp3D-OAHTS) platform, which achieves superior throughput compared to existing reported systems for 3D organoid drug screening. Utilizing this automated platform, we generated more than 10,000 homogeneous 3D organoid domes of neuroendocrine cervical cancer (NECC) and evaluated their drug responses to 2802 compounds in 13 days. This highly efficient and reproducible approach finally enabled the identification of 5 top hits that significantly inhibited NECC organoids in vitro with half-maximal inhibitory concentration (IC50) of lower than 10 nM. The representative candidate, Quisinostat 2HCl, demonstrated significantly stronger anti-tumor efficacy than clinically used agents in vivo. This platform significantly improves the rapidity and efficiency of 3D ECM-encapsulated organoid drug screening and facilitates new drug discovery for rare diseases.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai 200438, China.
- Institute of Organoid Technology, Kunming Medical University, Kunming 650500, China.
- School of Basic Medical Sciences, Institute of Biomedical Innovation, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang 330031, China.
- Z Lab, bioGenous BIOTECH, Shanghai 200438, China.
ORCID-Profile: Zhaoting Xu, Bing Zhao
Zitieren
APA
Xu, Z., Yang, H., Zhou, Y., Dzakah, E. E., & Zhao, B. (2025). Whole-process 3D ECM-encapsulated organoid-based automated high-throughput screening platform accelerates drug discovery for rare diseases. Life Medicine, 4(5). https://doi.org/10.1093/lifemedi/lnaf021
Vancouver
Xu Z, Yang H, Zhou Y, Dzakah EE, Zhao B. Whole-process 3D ECM-encapsulated organoid-based automated high-throughput screening platform accelerates drug discovery for rare diseases. Life Medicine. 2025;4(5). doi:10.1093/lifemedi/lnaf021
BibTeX
@article{Xu2025,
author = {Xu, Zhaoting and Yang, Hui and Zhou, Yuru and Dzakah, Emmanuel Enoch and Zhao, Bing},
title = {Whole-process 3D ECM-encapsulated organoid-based automated high-throughput screening platform accelerates drug discovery for rare diseases},
journal = {Life Medicine},
year = {2025},
volume = {4},
number = {5},
doi = {10.1093/lifemedi/lnaf021}
}
EUVIMED